A. Bucsics

发表

Achieving equal and timely access to innovative anticancer drugs in the European Union (EU): summary of a multidisciplinary CECOG-driven roundtable discussion with a focus on Eastern and South-Eastern EU countries

A. Laslop, L. Makaroff, N. Wilking, 2019, ESMO Open.

Utilisation of the ESMO-MCBS in practice of HTA.

B. Godman, C. Wild, A. Bucsics, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

e-SPC - delivering drug information in the 21st century: developing new approaches to deliver drug information to prescribers.

Walter E Haefeli, Anna Bucsics, W. Haefeli, 2012, British journal of clinical pharmacology.

Personalizing health care: feasibility and future implications

Jan Jones, Steven Simoens, Fredrik Nilsson, 2013, BMC Medicine.

Guideline‐conformity of initiation with oral hypoglycemic treatment for patients with newly therapy‐dependent type 2 diabetes mellitus in Austria

W. Winkelmayer, M. Brookhart, M. Stedman, 2011, Pharmacoepidemiology and drug safety.

Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets

A. Haycox, S. Simoens, B. Wettermark, 2018, Front. Public Health.

Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation

A. Haycox, S. Simoens, B. Godman, 2017, Front. Pharmacol..

Comparative effectiveness of branded vs. generic versions of antihypertensive, lipid-lowering and hypoglycemic substances: a population-wide cohort study

G. Heinze, W. Winkelmayer, Milan Hronsky, 2020, Scientific Reports.

Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs

T. Cars, R. Malmström, L. Gustafsson, 2014, Front. Pharmacol..

European collaboration on relative effectiveness assessments: What is needed to be successful?

M. Huic, M. Pavlovic, B. Wieseler, 2015, Health policy.

HTA programme response to the challenges of dealing with orphan medicinal products: Process evaluation in selected European countries.

L. Annemans, K. Facey, E. Nicod, 2017, Health policy.

Current Topics in Drug Reimbursement

A. Bucsics, R. Sauermann, V. Nell-Duxneuner, 2016 .

Payers' Views of the Changes Arising through the Possible Adoption of Adaptive Pathways

A. Haycox, S. Simoens, B. Godman, 2016, Front. Pharmacol..

Bucsics, Anna and Godman, Brian and Burkhardt, Thomas and Schmitzer, Manuela and Malmstrom, Rickard (2012) Influence of lifting prescribing restrictions for losartan on subsequent sartan utilisation patterns in Austria : implications for other countries. Expert Review of Pharmacoeconomics and Outcom

B. Godman, A. Bucsics, Anna Bucsics, 2018 .

Influence of lifting prescribing restrictions for losartan on subsequent sartan utilization patterns in Austria: implications for other countries

R. Malmström, B. Godman, A. Bucsics, 2012, Expert review of pharmacoeconomics & outcomes research.

Prevalence and determinants of unintended double medication of antihypertensive, lipid‐lowering, and hypoglycemic drugs in Austria: a nationwide cohort study

G. Heinze, W. Winkelmayer, Milan Hronsky, 2016, Pharmacoepidemiology and drug safety.

Potential Savings in Prescription Drug Costs for Hypertension, Hyperlipidemia, and Diabetes Mellitus by Equivalent Drug Substitution in Austria: A Nationwide Cohort Study

G. Heinze, W. Winkelmayer, Milan Hronsky, 2015, Applied Health Economics and Health Policy.

Impact of recent reforms in Austria on utilization and expenditure of PPIs and lipid-lowering drugs: implications for the future

B. Wettermark, B. Godman, A. Bucsics, 2009, Expert review of pharmacoeconomics & outcomes research.

Insight into recent reforms and initiatives in Austria: implications for key stakeholders

A. Haycox, H. Seyfried, B. Godman, 2008, Expert review of pharmacoeconomics & outcomes research.

The European challenges of funding orphan medicinal products

M. Kamusheva, G. Petrova, A. Bucsics, 2018, Orphanet Journal of Rare Diseases.

LOOKING BACK ON 5 YEARS OF HORIZON SCANNING IN ONCOLOGY

P. Krippl, C. Wild, A. Bucsics, 2016, International Journal of Technology Assessment in Health Care.

Impact of reimbursement changes on statin use among patients with diabetes in Austria

W. Winkelmayer, A. Bucsics, M. Alan Brookhart, 2010, Wiener klinische Wochenschrift.

Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future

S. Simoens, S. Jan, B. Godman, 2016, Front. Pharmacol..

The use of TNF-inhibitors in ankylosing spondylitis in Austria from 2007 to 2009 - a retrospective analysis.

A. Bucsics, B. Reichardt, V. Nell-Duxneuner, 2012, International journal of clinical pharmacology and therapeutics.

Proposal for a regulation on health technology assessment in Europe – opinions of policy makers, payers and academics from the field of HTA

A. Haycox, S. Simoens, S. Campbell, 2019, Expert review of pharmacoeconomics & outcomes research.

Discounts and rebates granted to public payers for medicines in European countries

A. Bucsics, S. Vogler, N. Zimmermann, 2012, Southern med review.

Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?

Andy Gray, Brian Godman, Ilse Truter, 2015, Expert review of clinical pharmacology.

Dabigatran – a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs

A. Haycox, S. Simoens, R. Malmström, 2013, Front. Pharmacol..

Initiatives to enhance renin–angiotensin prescribing efficiency in Austria: impact and implications for other countries

B. Wettermark, B. Godman, A. Bucsics, 2010, Expert review of pharmacoeconomics & outcomes research.

Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications

Brian Godman, Samantha Alvarez-Madrazo, Stephen Campbell, 2014, Front. Pharmacol..

Systemic Measures and Legislative and Organizational Frameworks Aimed at Preventing or Mitigating Drug Shortages in 28 European and Western Asian Countries

Steven Simoens, Bogdan Asanin, Vincent Hargaden, 2018, Front. Pharmacol..

W. Winkelmayer, A. Bucsics, Michaela Pogantsch, 2007, European Journal of Epidemiology.

Comparative effectiveness of branded vs. generic versions of antihypertensive, lipid-lowering and hypoglycemic substances: a population-wide cohort study

G. Heinze, W. Winkelmayer, Milan Hronsky, 2020, Scientific Reports.

Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation

A. Haycox, S. Simoens, B. Godman, 2017, Front. Pharmacol..

Can authorities appreciably enhance the prescribing of oral generic risperidone to conserve resources? Findings from across Europe and their implications

K. Bennett, S. Simoens, M. Petzold, 2014, BMC Medicine.

Assessing the Accuracy of Sales Forecasts Submitted by Pharmaceutical Companies Applying for Reimbursement in Austria

M. Freissmuth, A. Bucsics, M. Kossmeier, 2021, Frontiers in Pharmacology.

Different initiatives across Europe to enhance losartan utilization post generics: impact and implications

K. Bennett, S. Simoens, M. Petzold, 2014, Frontiers in Pharmacology.

Potential to Enhance the Prescribing of Generic Drugs in Patients with Mental Health Problems in Austria; Implications for the Future

L. Gustafsson, C. Barbui, M. Bennie, 2013, Front. Pharmacol..